GE HealthCare has announced plans to acquire icometrix, an AI‑powered brain imaging company, in a bid to strengthen its neurological imaging offerings and create seamless MRI‑analysis workflows. The deal is aligned with GE’s precision care strategy and aims to integrate icometrix’s icobrain platform with GE’s MRI systems for enhanced clinical support.
The icobrain suite includes icobrain aria, which is the first FDA‑cleared AI solution for detecting and quantifying side effects (ARIA) associated with amyloid‑targeting Alzheimer’s therapies. GE intends to expand access to icobrain aria even across non‑GE MRI hardware, offering longitudinal tracking of ARIA‑E and ARIA‑H in treatment monitoring.
Currently, GE’s neurology portfolio spans MR and PET scanners, advanced visualisation tools, and MIMneuro software for amyloid imaging quantification. The acquisition is expected to help clinicians manage the growing demand for neurological MRI – driven by rising Alzheimer’s prevalence and expanded use of anti‑amyloid treatments.
GE will fund the acquisition from cash reserves. The deal remains subject to regulatory approval and customary closing conditions; financial terms were not disclosed.
This news item has been summarised using AI and checked by humans before publication. Read the full release here.
Sign up to the ACNR email newsletter here: https://acnr.co.uk/about-acnr/email-signup/
Sign up for our online community for neurology specialists: https://acnr.co.uk/acnr-online-community-signup/
